- Home
- CAPR vs BNTC Comparison
CAPR vs BNTC Comparison
Compare CAPR & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- BNTC
- Stock Information
- Founded
- CAPR 2005
- BNTC 1995
- Country
- CAPR United States
- BNTC United States
- Employees
- CAPR N/A
- BNTC N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- BNTC Health Care
- Exchange
- CAPR Nasdaq
- BNTC Nasdaq
- Market Cap
- CAPR 322.7M
- BNTC 335.5M
- IPO Year
- CAPR N/A
- BNTC N/A
- Fundamental
- Price
- CAPR $7.10
- BNTC $12.99
- Analyst Decision
- CAPR Strong Buy
- BNTC Strong Buy
- Analyst Count
- CAPR 8
- BNTC 5
- Target Price
- CAPR $24.75
- BNTC $26.00
- AVG Volume (30 Days)
- CAPR 1.7M
- BNTC 41.1K
- Earning Date
- CAPR 08-11-2025
- BNTC 09-25-2025
- Dividend Yield
- CAPR N/A
- BNTC N/A
- EPS Growth
- CAPR N/A
- BNTC N/A
- EPS
- CAPR N/A
- BNTC N/A
- Revenue
- CAPR $13,392,150.00
- BNTC N/A
- Revenue This Year
- CAPR $16.24
- BNTC N/A
- Revenue Next Year
- CAPR $328.11
- BNTC N/A
- P/E Ratio
- CAPR N/A
- BNTC N/A
- Revenue Growth
- CAPR N/A
- BNTC N/A
- 52 Week Low
- CAPR $3.98
- BNTC $8.06
- 52 Week High
- CAPR $23.40
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- CAPR 42.24
- BNTC 58.50
- Support Level
- CAPR $6.90
- BNTC $12.04
- Resistance Level
- CAPR $8.00
- BNTC $13.09
- Average True Range (ATR)
- CAPR 0.55
- BNTC 0.63
- MACD
- CAPR -0.02
- BNTC 0.18
- Stochastic Oscillator
- CAPR 7.91
- BNTC 93.47
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.